SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. It aggregates components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:


•	Japan


•	EMEA


•	North America Plasma


•	All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation and certain legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During the first quarter of fiscal 2019, management reorganized its operating segments such that certain immaterial components of EMEA are now reported as components of All Other. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2019. These changes did not have an impact on its ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Selected information by business segment is presented below:



	Three Months Ended						Nine Months Ended
(In thousands)	December 29, 2018			December 30, 2017			December 29, 2018			December 30, 2017
Net revenues
Japan	$	18,297		$	18,161		$	52,244		$	50,557
EMEA	42,056			44,860			123,395			126,727
North America Plasma	104,163			86,545			295,392			249,132
All Other	85,282			86,338			250,576			249,632
Net revenues before foreign exchange impact	249,798			235,904			721,607			676,048
Effect of exchange rates	(2,442		)	(1,861		)	(3,323		)	(5,677		)
Net revenues	$	247,356		$	234,043		$	718,284		$	670,371



	Three Months Ended						Nine Months Ended
(In thousands)	December 29, 2018			December 30, 2017			December 29, 2018			December 30, 2017
Segment operating income
Japan	$	9,580		$	9,715		$	27,213		$	25,838
EMEA	11,427			12,633			34,926			33,157
North America Plasma	43,392			34,160			123,456			96,052
All Other	34,460			34,729			103,730			97,929
Segment operating income	98,859			91,237			289,325			252,976
Corporate operating expenses	(58,314		)	(52,164		)	(174,831		)	(150,670		)
Effect of exchange rates	2,133			2,755			7,782			1,656
Restructuring and turnaround costs	(1,791		)	(31,298		)	(7,258		)	(39,568		)
Deal amortization	(6,131		)	(6,506		)	(18,667		)	(19,501		)
Asset impairments	—			—			(21,170		)	—
Accelerated depreciation	(4,822		)	(3,011		)	(13,203		)	(3,011		)
Legal charges	(1,614		)	—			(2,289		)	—
Operating income	$	28,320		$	1,013		$	59,689		$	41,882

The Company's products are organized into three categories for purposes of evaluating their growth potential: Plasma, Blood Center and Hospital. Management reviews revenue trends based on these business units.

Net revenues by business unit are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 29, 2018		December 30, 2017		December 29, 2018		December 30, 2017
Plasma	$	131,823	$	113,098	$	373,078	$	324,376
Blood Center	67,155		74,227		199,881		211,502
Hospital	48,378		46,718		145,325		134,493
Net revenues	$	247,356	$	234,043	$	718,284	$	670,371

Net revenues generated in the Company's principal operating regions on a reported basis are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 29, 2018		December 30, 2017		December 29, 2018		December 30, 2017
United States	$	157,457	$	140,840	$	452,523	$	410,671
Japan	17,734		17,664		52,295		49,312
Europe	40,977		42,189		119,075		118,544
Asia	29,166		30,733		89,136		85,504
Other	2,022		2,617		5,255		6,340
Net revenues	$	247,356	$	234,043	$	718,284	$	670,371